Oncotelic Therapeutics Stock Fundamentals
Oncotelic Therapeutics fundamentals help investors to digest information that contributes to Oncotelic Therapeutics' financial success or failures. It also enables traders to predict the movement of Oncotelic OTC Stock. The fundamental analysis module provides a way to measure Oncotelic Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncotelic Therapeutics otc stock.
Oncotelic |
Oncotelic Therapeutics OTC Stock Return On Equity Analysis
Oncotelic Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Oncotelic Therapeutics Return On Equity | 0.5 |
Most of Oncotelic Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncotelic Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Oncotelic Therapeutics has a Return On Equity of 0.4967. This is 102.07% lower than that of the Healthcare sector and 101.36% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably lower than that of the firm.
Oncotelic Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Oncotelic Therapeutics's current stock value. Our valuation model uses many indicators to compare Oncotelic Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oncotelic Therapeutics competition to find correlations between indicators driving Oncotelic Therapeutics's intrinsic value. More Info.Oncotelic Therapeutics is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Oncotelic Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Oncotelic Therapeutics' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Oncotelic Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncotelic Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Oncotelic Therapeutics could also be used in its relative valuation, which is a method of valuing Oncotelic Therapeutics by comparing valuation metrics of similar companies.Oncotelic Therapeutics is currently under evaluation in return on equity category among its peers.
Oncotelic Fundamentals
| Return On Equity | 0.5 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 31.34 M | ||||
| Shares Outstanding | 391.11 M | ||||
| Shares Owned By Insiders | 55.93 % | ||||
| Number Of Shares Shorted | 662.75 K | ||||
| Price To Earning | 2.16 X | ||||
| Price To Book | 0.89 X | ||||
| Price To Sales | 8.40 X | ||||
| Gross Profit | 1.74 M | ||||
| EBITDA | (8.45 M) | ||||
| Net Income | (9.39 M) | ||||
| Cash And Equivalents | 399.77 K | ||||
| Total Debt | 9.8 M | ||||
| Debt To Equity | 0.40 % | ||||
| Current Ratio | 0.03 X | ||||
| Book Value Per Share | 0.06 X | ||||
| Cash Flow From Operations | (4.43 M) | ||||
| Short Ratio | 8.04 X | ||||
| Earnings Per Share | 0.02 X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 16 | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 23.9 M | ||||
| Total Asset | 23.61 M | ||||
| Z Score | 1.2 | ||||
| Net Asset | 23.61 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Oncotelic OTC Stock
If you are still planning to invest in Oncotelic Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncotelic Therapeutics' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |